BioMedSyn
Search drugs, diseases, clinical trials, targets, patents, companies, news, publications, and more
One-stop shop in Biomedical Knowledge & Decision Making
AI Data Synchronization & Expansion
Expert Data Curation
Domain Knowledge AI Assistant
Streamline your journey to
Biomedical knowledge
Register
Stay up-to-date with the
latest from BioMedSyn
- Special Requests
- Report an error
- Additional Functionalities
- Academic Researchers
- Learn More
- More Statistics
- Data Sources
- Classifications
- Support
- FAQs
- Help Center
- To Know
- Terms of Use
- Privacy Policy
- Report an error
- Additional Functionalities
- I'm an Academic Researcher
- More Statistics
- Data Sources
- Classifications
- FAQs
- Help Center
- Terms of Use
- Privacy Policy
- Apogee Therapeutics APEX Phase 2 Part A Readout
Apogee Therapeutics, Inc.24 hours ago
- Corporate Presentation – June 2025
Molecular Partners Ag120 hours ago
- Biogen to Report Second Quarter 2025 Financial Results July 31, 2025
Biogen Inc.144 hours ago
- Cellectar Biosciences Announces Closing of $6.9 Million Underwritten Public Offering, including Full Exercise of Over-Allotment Option
Cellectar Biosciences, Inc.144 hours ago
- 4DMT Announces Accelerated 4D-150 Phase 3 Development in Wet AMD and Streamlined Organization to Drive Late-Stage Execution
4d Molecular Therapeutics, Inc.144 hours ago
- Windtree Announces Issuance of Istaroxime Patent for the United States for Acute Heart Failure
Windtree Therapeutics, Inc.144 hours ago
- Corbus Pharmaceuticals Holdings, Inc.: Clinical Trials. Advancing Research and Patient Care with CRB-701, CRB-601, and CRB-913 Through Research
Corbus Pharmaceuticals Holdings, Inc.153 hours ago
- Corbus Pharmaceuticals Holdings, Inc.: CRB-913. Clinical-Stage CB1 Inverse Agonist for Obesity Treatment
Corbus Pharmaceuticals Holdings, Inc.153 hours ago
- Corbus Pharmaceuticals Holdings, Inc.: CRB-601. Clinical-Stage TGF-β Targeted Immunotherapy for Solid Tumors
Corbus Pharmaceuticals Holdings, Inc.153 hours ago
- Corbus Pharmaceuticals Holdings, Inc.: CRB-701. Clinical-Stage Nectin-4 Targeted Cancer Treatment
Corbus Pharmaceuticals Holdings, Inc.153 hours ago
- Corbus Pharmaceuticals Holdings, Inc.: Our Pipeline. Clinical-Stage Therapies for Oncology and Obesity
Corbus Pharmaceuticals Holdings, Inc.153 hours ago